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Summ~ry 
Polymorphonuclear neutrophil (PMN) accumulation within damaged tissues, a hallmark of acute 
inflammation, is dependent upon initial adhesion to endothelial cells.  In vitro studies suggest 
that P-selectin and platelet activating factor (PAF) are key molecules in this process by promoting 
the initial adhesion of PMN to endothelial cells. We report in vivo studies in which intravenous 
administration of lipopolysaccharide (LPS)  to anesthetized rats caused a very rapid onset (<5 
min) of neutropenia, in association with induction of surface expression of P-selectin on microvascular 
endothelial cells in kidney, liver and lung; analogous induction of P-selectin expression by cultured 
endothelial cells was observed in response to LPS stimulation in vitro.  In addition, treatment 
with an antibody (Ab) to P-selectin (or use of a PAF antagonist) blocked development of neutropenia 
in vivo for at least 15 min post-LPS injection,  and Ab treatment was shown to block PMN 
accumulation in tissues. These studies document roles for P-selectin and PAF in the early adhesion 
of PMN to endothelial cells in vivo. 
I 
nflammation is usually a beneficial process leading to de- 
struction or isolation of injurious agents and tissue repair. 
However, in situations such as gram-negative sepsis, this re- 
sponse may be excessive, and cellular infiltration, endothelial 
damage, and vascular leakage can lead to extensive tissue in- 
jury. Accumulation of leukocytes, particularly PMN,  is an 
important and early component of this inflammatory response 
(1). A three-step mechanism for the binding of PMN to en- 
dothelial cells is proposed (2), whereby reversible  adhesion 
through binding to selectin molecules is followed by PMN 
activation and activation-dependent binding. The nature of 
the molecules involved in these interactions appears  to de- 
pend upon the type and length of exposure of the inflamma- 
tory stimulus. P-selectin (also known as CD-62, GMP-140, 
or PADGEM) is normally located in r  granules of platelets 
and the Weibel-Palade bodies of endothelial cells, but is rap- 
idly expressed on the surface of stimulated endothelial cells 
(3, 4). Surface-expressed P-selectin mediates the "rolling" of 
PMN, whereby the cells are slowed and brought into close 
vicinity of the endothelium, allowing further adhesive inter- 
actions to occur (5). In vitro, P-selectin expression is rapidly 
induced by thrombin or histamine, peaks at 5-10 min after 
stimulation and, because of reinternalization, is largely ab- 
sent by 20 rain (3, 6), suggesting that a transient appearance 
in membrane P-selectin may be of significance in some of 
the earliest events of inflammation. 
Platelet activating factor (PAF) is a potent, biologically- 
active phospholipid implicated in many inflammatory reac- 
tions, including endotoxic shock (1) and endotoxin-induced 
lung injury (7). Like P-selectin, PAF expression by endothelial 
cells is maximal within 5-10 min of stimulation and returns 
to background levels shortly thereafter (6, 8). PAF contributes 
to PMN adhesion and activation,  and PAF-primed PMNs 
damage endothelial cells (1, 9). Moreover, treatment of en- 
dothelial cells with the combination of an anti-P-selectin Ab 
and PAF-antagonist completely blocks PMN adhesion in vitro 
(6). This observation, plus the rapid and transient nature of 
their surface-bound expression on endothelial cells, have led 
to the concept that P-selectin and PAF act synergistically in 
promoting  the  early adhesion  of PMN  to  endothelium. 
Specifically, rapid endothelial expression of P-selectin could 
mediate the initial tethering of PMN to endothelial cells, in- 
dependently of CDll/CD18 ~ integrins, whereas associated 
endothelial PAF expression induces juxtacrine activation of 
surface CDll/18 molecules on PMN and their high affinity 
binding to endothelial-expressed ICAM molecules (2, 6, 9). 
Targeting of P-selectin and PAF may thereby prove of ther- 
apeutic efficacy in blocking initial  PMN  adhesion to  en- 
dothelium in vivo. 
To this end, since LPS is present within the cell wall of 
gram-negative bacteria, is implicated in the pathogenesis of 
septic shock (10), and is known to induce a marked neutropenia 
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of P-selectin and PAF in early PMN adhesion to endothelium 
in vivo, using  a  rat  model of systemic endotoxemia. 
Materials and Methods 
Reagents and Cells.  LPS and lactoperoxidase were purchased from 
Sigma Chemical Co. (St. Louis, MO). RPMI 1640 and FCS were 
obtained from Whittaker Bioproducts (Walkersville, MD), and 1~I 
was  supplied by Amersham  Radiochemicals  (Amersham,  UK). 
Thrombin was purified as described (12). Details of a blocking, 
af~nity-purified  rabbit  anti-human  P-selectin  Ab  and  control, 
nonimmune rabbit IgG (13), plus a method for their pepsin diges- 
tion and purification as F(ab')2 fragments, were reported previously 
(14). Anti-rat PMN mAb (RP-3) (15) was a gift of Dr. F. Sendo 
(Yamagata University School of Medicine, Yamagata, Japan). The 
synthetic PAF analogue, CV-3988 (16), was obtained from Takeda 
Chemical Industries (Osaka, Japan) and dissolved in 0.9% saline 
just before injection. HLo60 cells, obtained from American Type 
Culture Collection (Rockville, MD),  were cultured under stan- 
dard conditions, and platelets were isolated from citrated plasma (13). 
Effect of Anti-P-selectin Ab on Rat P-selectin In Vitro.  The ability 
of anti-P-selectin  Ab to block rat P-selectin  was tested by study 
of neutralization of rat platelet rosette formation with HL-60 cells 
(13).  Briefly,  thrombin-activated  human  or  rat  platelets  (2  x 
10S/ml) were preincubated with specific Ab or control Ig for 20 
min before addition to HL-60 cells (2  x  106/ml); platelet roset- 
ting was evaluated on a cell suspension  by scoring a minimum of 
100 cells/assay. 
Induction of P-selectin on Endothelial Cells In Vitro.  Human um- 
bilical  endothelial cells  were cultured in  25-cm  2 flasks  (Costar 
Corp.,  Cambridge,  MA) according to Jaffe et al.  (17). Actively 
growing,  subconfluent cultures (second passage,  ,~10,000 cells/ 
well), or in two experiments, confluent endothelial cell cultures, 
were washed six times in buffer (PBS/0.5% human serum albumin), 
stimulated with thrombin (1 U/ml) or LPS (1 #g/ml) for 10 min 
at  room temperature,  and washed  six times in buffer.  Surface- 
radiolabeling  using 12SI-lactoperoxidase,  immunoprecipitation with 
anti-P-selectin  or control Ab, and analysis by gel electrophoresis 
and autoradiography were performed as described by Goding (18). 
Briefly, endothelial cells were iodinated, scraped,  and solubilized 
using  0.1  M-Tris/0.1%  EDTA/0.1%  NP-40  (1  h,  4~  nuclei 
pelleted by centrifugation, and the endothelial cells lysate precleared 
by two incubations with nonimmune serum, followed by specific 
Ab, six washes, SDS-PAGE (10% gels run under reducing condi- 
tions),  and autoradiography overnight at  -70~ 
In  Vivo Model of Endotoxemia.  Specific-pathogen-free male 
Brown Norway rats (100-200 g) were obtained from the Animal 
Resource Center (Willetton, WA). To assess the effects of endo- 
toxin administration on circulating PMN, rats were anesthetized 
with ether and injected with LPS (5 mg/kg i.p.).  The effects of 
P-selectin Ab were determined by intravenous injection of whole 
or F(ab')2-fragment  of anti-P-selectin  Ab or control rabbit Ig im- 
mediately before LPS administration. An Ab concentration of 2.5 
mg/kg was used, based upon preliminary dose/response data. The 
PAF antagonist,  tested at doses from 5-40 mg/kg, was injected 
pre-LPS,  either alone or in combination with anti-P-selectin  Ab. 
Blood samples  (0.5 ml) were collected in sterile  glass tubes con- 
taining 10 #M EDTA just before LPS injection, and thereafter at 
5-min intervals for 20 min, to allow serial analysis of PMN levels 
and, as appropriate, measurement of the concentration of rabbit 
Ig.  Data  were  collected  from  five  rats/treatment  group  per 
time-point. 
Quantitation of  Circulating  PMN.  Acridine orange/ethidium bro- 
mide (0.1%) was added to aliquots of blood, to assist in recogni- 
tion of leukocytes vs. RBC, and total leukocyte counts were per- 
formed using a Neubauer hemocytometer under a phase microscope 
equipped for fluorescent microscopy. Differential cell counts were 
performed on hematoxylin and eosin-stained, methanol-fixed blood 
smears; 500 leukocytes/smear were counted, and total PMN numbers 
were determined by reference to total leukocyte counts. Given vari- 
able PMN counts, results were expressed  as a percentage of the 
PMN  count  for that  animal  pre-LPS  injection.  The statistical 
significance of  data was assessed using the Instat program (GraphPad 
Software, San Francisco, CA); p <0.05 in the nonparametric Mann- 
Whitney U-test was considered significant. 
Detection oJ Rabbit Ig by ELISA.  Serial circulating levels of  rabbit 
Ig in Ab-injected rats  were determined by ELISA,  as described 
(14), using appropriate peroxidase-conjugated  goat antibodies (The 
Jackson Laboratories,  Bar Harbor, ME) to detect either whole or 
F(ab')2-Ab fragments. 
Immunohistologic  Studies.  After rats were killed under anesthesia, 
lung, liver, and kidney tissues were removed from normal or LPS- 
injected rats (5, 10, 15, or 20 min post-injection), plus rats given 
rabbit Ab (anti-P-selectin  or control Ig) or PAF antagonist before 
LPS injection. Tissues were snap-frozen in liquid nitrogen and stored 
at -70~  P-selectin expression and PMN infiltration were assessed 
in cryostat sections stained using a peroxidase-antiperoxidase method 
(19). Since preliminary studies showed a close correlation between 
morphologic detection and RP3 mAb labeling,  PMN infiltration 
was determined by counting RP3 +  cells (20 high power fields/tissue 
section, 3 levels within each tissue) and comparing data between 
groups (n  =  3/group),  as described for circulating PMN. 
Results  and  Discussion 
Anti-P-selectin  Ab Blocks  Rat P-selectin Function  In  Vitra 
Anti-P-selectin Ab blocked the binding of thrombin-activated 
human rat platelets to HL-60 cells in vitro (Fig. 1), whereas 
control rabbit Ig had no effect, indicating the ability of an 
anti-human P-selectin Ab to block rat P-selectin, as was also 
reported by Mulligan  et al.  (20). 
LPS Stimulates  Surface Expression  of P-selectin by Cultured 
Endothelial  Cells.  Treatment  of endothelial  cells  in  vitro 
(whether subconfluent or confluent) with thrombin or LPS 
resulted in the surface expression of a 140-kD protein as shown 
by SDS-PAGE analysis (Fig. 2). Analogous results were seen 
by immunofluorescent staining of cultured endothelial cells 
80 
~ 60  Figure 1.  Neutralization  of rat 
o  P-selectin in vitro by anti-P-selec- 
.~1  tin Ab. Rosetting of HL-60 cells 
"1" 40  (:hdedbYathr~  human 
bars) or rat platelets (open 
(s~)e~tiFnab fragments of anti-P- 
bars) in the presence  of  buffer  alone 
0  at 5 #g/ml (B), or 100 
#g/ml (C), or Fab fragments of 
20  sults are representative  of three ex- 
~  rabbit Ig at 100 #g/ml (D). Pe- 
A  B  C  D  periments. 
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dothelial call surface  expression  of 
P-selectin by  LPS  (or  control 
thrombin). Endothelial cells  were 
treated with  tissue culture me- 
dium alone (lane A), or medium 
plus thrombin (lane B), or LPS 
(lane C), followed  by surface  radi- 
olabeling, lysis, immunoprecipita- 
tion with affanity-purified  rabbit 
anti-P-selectin Ab, separation by 
10% SDS-PAGE  under reducing 
conditions, and autoradiography. 
Molecular weight markers were 
myosin (200,000), 3-galactosi- 
dase (116,000), phosphorylase B 
(97,000),  BSA  (66,000), OVA 
(45,000). 
(data not shown). These data show that LPS, like the known 
agonists, histamine,  and thrombin (6), can rapidly stimulate 
P-selectin  surface expression by endothelial  cells. 
Immunoperoxidase Localization of  P-selectin.  Sections of lung, 
liver,  and  kidney  from  normal  rats  lacked  demonstrable 
P-selectin, whereas surface microvascular endothelial labeling 
was seen within 5 rain of LPS administration  (Fig. 3). Such 
expression of P-selectin upon LPS stimulation  must reflect 
transport  from a preformed pool, given the rapidity of the 
response.  LPS  was  recently  shown  to  transiently  induce 
mRNA in mouse liver,  lung,  kidney, and heart,  with peak 
mRNA detected at 4 h post-stimulation  (21);  such mRNA 
induction presumably precedes synthesis and replacement of 
depleted cytoplasmic P-selectin  stores. The lack of cytoplasmic 
labeling for P-selectin in unstimulated cells may reflect masking 
of the particular epitope(s) recognized by the Ab used, and 
contrasts with another Ab to P-selectin that reportedly recog- 
nizes the molecule within cytoplasmic Weibel-Palade bodies 
but not after its surface expression by stimulated endothelial 
cells  (22). 
A nti-P-selectin  A b Administration Blocked LPS-induced PMN 
Pooling in Various Organs.  RP3 +  PMN were present in vari- 
able and often large numbers within sections of normal lungs 
of specific  pathogen-free  rats,  which limited  assessment of 
the extent of pooling caused by LPS administration,  and the 
ability of an anti-P-selectin Ab to block such accumulation. 
By contrast,  sections of normal  liver or kidney from  such 
animals  essentially lacked PMN  (Table 1),  allowing  assess- 
ment of the effects of LPS administration. Both organs showed 
infiltration  by large numbers of PMN by 15 rain post-LPS 
injection in a comparable distribution to that seen for newly 
expressed P-selectin (Fig. 3), whereas P-selectin Ab, but not 
control Ig, caused a highly significant level of inhibition  of 
such PMN  accumulation  (Table  1,  Fig.  3). 
Anti-P-selectin Ab Administration Blocked LPS-induced Neu- 
tropenia In  Viva  Consistent  with its effects on pooling of 
PMN in various tissues, intravenous LPS caused a rapid and 
sustained neutropenia  (Fig.  4).  Within  5 rain  of injection, 
circulating  PMN  levels  dropped  to  <40%  of normal  and 
thereafter remained at 20-40% of pretreatment values. These 
findings suggest that the PMN were removed from the cir- 
culation by adherence to rapidly induced endothelial  adhe- 
sion molecules, or simply by pooling within highly vascular- 
ized tissues in the absence of increased endothelial adhesivity, 
or a combination  of the  two. 
Adherence  of PMN  to P-selectin in vivo was shown by 
the effect of injection of anti-P-selectin Ab immediately be- 
fore LPS administration,  which resulted in the maintenance 
of PMN levels at >190% of baseline for the first 15 min (Fig. 
4).  Results were significantly greater than  in rats receiving 
LPS plus control  Ig (Mann-Whitney  U-test, p  <0.01  at  5 
and  10  rain),  and  comparable  effects were  seen  using  an 
F(ab')2  fragment  of the  anti-P-selectin  Ab  (not  shown). 
Treatment with control rabbit Ab (Fig. 4) did not significantly 
differ from treatment with LPS alone (Mann-Whitney U-test; 
p >0.2 at all time points).  Regardless of anti-P-selectin Ab 
administration,  PMN  counts in LPS-injected animals  pro- 
gressively declined after 15-20 min.  This effect was not due 
to  clearance  of whole  or  F(ab')2  Ab  from  the  circulation 
since ELISA measurements  showed persistence of rabbit Ig 
levels at/>5 #g/ml at all times (not shown). These data sug- 
gest that the rapid onset of neutropenia induced by LPS ad- 
ministration is due to adhesion of PMN to P-selectin expressed 
on the surface of endothelial ceils, but that P-selectin expres- 
sion is not the mechanism for persistence of neutropenia be- 
yond 15-20 rain post-LPS injection in this model.  Anti-P- 
selectin Ab  treatment  had  no effect on LPS-induced TNF 
production in vivo as assessed by assay of serum samples (not 
shown). 
Pretreatment with a PAF Antagonist Blocked LPS-induced Neu- 
tropenia,  Pretreatment of animals with the PAF antagonist 
(40 mg/kg) maintained PMN counts at 90-100% of normal 
at all time-points to 20 rain despite LPS injection (Fig.  5). 
Lower doses of PAF antagonist had progressively less efficacy 
in blocking development  of neutropenia,  and by 5 mg/kg 
had no significant effect at all.  No synergy between anti-P- 
selectin Ab and PAF antagonist in blocking the early effects 
of LPS was found, possibly due to the potency of each agent 
when  given at the dose indicated,  or the  sequential  rather 
than concomitant expression on endothelial cells of each mol- 
ecule or their receptors.  Detailed evaluation  of multiple dosage 
Table  1.  Anti-P.selectin  Ab Blocks PMN Accumulation in 
Kidney and Liver 
Treatment  group  Liver  Kidney 
Nil  0.3  +_  0.5*  0.1  _+ 0.3* 
LPS  8.7  +  5.6  14.6  _+  7.7 
LPS/control Ig  9.5  _+  7.1  12.9  +  6.2 
LPS/anti-P-selectin  Ab  0.5  _+  0.4*  0.6  +  0.6* 
All values indicate mean -+ SD PMN/high power field in normal rats 
or 15 min post-injection  with LPS _+ Ab, as indicated, using 20 fields/rat 
and 3 rats/group. 
* jv <0.0001 compared with LPS or LPS/control Ig-treated groups. 
331  Coughlan  et al.  Brief  Definitive Report Figure 3.  Immunoperoxidase localization of P-selectin and PMN in cryostat sections of rat liver (a-d) and kidney (e-h). (a) No labeling for P-selectin 
was seen in rat liver before injection of LPS, whereas (b) at 5 min post-LPS injection,  P selectin was demonstrated  on sinusoidal capillaries as well 
as arterioles (granular labeling, lower right) and venules. (c) Sections of livers from rats injected with LPS and anti-P-selectin Ab lacked significant PMN 
infiltration (one RP-3+ PMN is present, lower center) at 15 min post-LPS injection; but (d) corresponding sections from rats receiving LPS plus control 
Ig showed widespread PMN infiltration.  Similarly to liver, (e) sections of kidneys from normal rats lacked P-selectin expression, including glomeruli 
(G), whereas (J) within 5 min of LPS injection, widespread microvascular labeling for P-selectin was detected,  including G capillaries, intertubular 
capillaries, and arterioles; the contracted arteriole at center top of the panel shows dense surface labeling in association with multiple  adherent leukocytes. 
(g) Treatment with an anti-P-selectin Ab blocked PMN infiltration, as assessed by labeling with RP3 mAb at  15 min post-LPS injection,  whereas 
(h) many PMN were detected within renal interstitial areas and glomeruli of corresponding rats injected with LPS plus control Ig. (Hematoxylin counter- 
stain; all panels  x400 original magnification,  except panel f,  x630.) 
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Effect of pretreatment  with anti-P-selectin Ab or control Ig  Figure  4. 
on LPS-induced neutropenia.  Circulating PMN counts (mean  _+  SEM) 
are shown (n =  5/time-point), expressed as a percentage of each animal's 
pretreatment  PMN  count.  Development  of LPS-induced neutropenia 
(--e-) was blocked by pretreatment with anti-P-selectin Ab (--U]-) but 
not control Ig (-O-). Results at 5 and 10 min post-LPS injection were 
highly significant (* p <0.01,  Mann-Whitney U-test)  in anti-P-selectin 
Ab-treated animals compared with the control Ab-treated group, whose 
PMN counts fell in close similarity to rats receiving LPS alone. Results 
at 15 and 20 rain post-LPS showed only marginally significant (p = 0.056) 
effects. 
combinations was precluded by the limited availability of the 
polyclonal Ab. In addition,  these studies do not preclude a 
role for the indirect action of endotoxin via effects on com- 
plement, platelets, histamine release, PMN deformability, or 
other factors (23, 24). 
These studies show that LPS causes a rapid and profound 
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Development  of  LPS-induced  neutropenia  (--0-)  Figure  5.  was 
blocked by pretreatment (--O-) with PAF antagonist (40 mg/kg); results 
were significant (*/, <0.05) at 5, 15, and 20 rain, and highly significant 
(** p <0.01) at 10 min post-LPS. 
degree of neutropenia in vivo, in association with stimula- 
tion of  endothelial cell surface P-selectin expression. Targeting 
of either P-selectin or PAF maintains circulating neutrophils 
levels and provides initial protection of the host against the 
potent effect of LPS. However, consistent with the transient 
expression of these molecules  shown by previous in vitro 
studies,  targeting of P-selectin  or PAF  does  not prevent 
progressive development of neutropenia after 20 min. These 
in vivo data provide evidence for an early and transient role 
of P-selectin and PAF in inflammation, and experimental sup- 
port  for a multistep model of leukocyte adhesion  to  en- 
dothelium. 
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